JAMA Intern Med:老年AMI患者使用β阻滞剂的利弊分析,全在这里!

2016-12-16 MedSci MedSci原创

尽管β-受体阻滞剂是急性心肌梗死(AMI)后的主要治疗药物,但是这些药物通常没有在AMI后的老年疗养院人群的处方中出现,部分原因是担心潜在的功能损害和受益的不确定性。来自美国的研究人员开展了一项研究,该研究的目的是探讨在接受长期护理的65岁及以上老年人群中,AMI后β受体阻滞剂与功能下降,死亡率和再住院的关系。该疗养院AMI居民队列研究于2007年5月1日至2010年3月31日期间进行,研究人员使

尽管β-受体阻滞剂是急性心肌梗死(AMI)后的主要治疗药物,但是这些药物通常没有在AMI后的老年疗养院人群处方中出现,部分原因是担心潜在的功能损害和受益的不确定性。

来自美国的研究人员开展了一项研究,该研究的目的是探讨在接受长期护理的65岁及以上老年人群中,AMI后β受体阻滞剂与心功能下降,死亡率和再住院的关系。

该疗养院AMI居民队列研究于2007年5月1日至2010年3月31日期间进行,研究人员使用了来自医疗保险A部分和D部分的国家数据。在AMI之前使用β受体阻滞剂的人群被排除此研究。研究人员基于倾向得分的方法比较了在AMI住院治疗之后启用β-阻滞剂治疗和不治疗人群的结果。

主要检测结果是AMI后的前90天功能衰退,死亡和再住院情况。在日常生活活动中研究人员使用Morris独立性量表来检测功能状态。

初始队列共包括15,720例患者(11,140例女性患者(70.9%)和4580例男性患者(29.1%);平均[SD]年龄,83[8]岁),包括8953例新的β受体阻滞剂使用者和6767例非使用者。倾向匹配队列包括5496例β-受体阻滞剂的新使用者和相等数量的未使用者,共有10,992名参与者(7788名女性[70.9%];3204名男性[29.1%];平均[SD]年龄,84[8]岁)。

β受体阻滞剂的使用者比不使用者更有可能经历功能下降(比值比[OR],1.14;95%CI,1.02-1.28),数量为52例(95%CI,32-141)。相反,β受体阻滞剂使用者比不使用者的死亡率更低(风险比[HR],0.74;95%CI,0.67-0.83),并具有相似的再住院率(HR,1.06;95%CI,0.98-1.14)。

具有中度或重度认知障碍或严重功能依赖性的疗养院人群特别容易经历β受体阻滞剂导致的功能下降(分别为OR,1.34;95%CI,1.11-1.61和OR,1.32;95%CI,1.10-1.59 )。相比之下,研究人员在具有完整认知或轻度痴呆的参与者中也发现了由于β-阻滞剂引起的功能下降的少量证据(OR,1.03;95%CI,0.89-1.20;P=0.03)(OR,0.99;95%CI,0.77-1.26)和功能独立性下降的中等程度证据(OR,1.05;95%CI,0.86-1.27)。β-阻断剂的死亡率改善作用在所有亚组中相似。

AMI后β阻滞剂的使用与重大认知功能损害的疗养院居民的功能显著下降有关,但β阻滞剂对那些具有相对保留的认知和功能的疗养院人群的功能下降没有影响。β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2017-09-11 lujian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2017-02-10 zhyy88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2016-12-17 owlhealth

    研究很不错,以前没太关注对认知的影响,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2016-12-17 yafeiliutjh

    有意义的研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1744806, encodeId=b4ce1e4480684, content=<a href='/topic/show?id=d8c6322986a' target=_blank style='color:#2F92EE;'>#利弊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32298, encryptionId=d8c6322986a, topicName=利弊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a8135449354, createdName=lujian, createdTime=Mon Sep 11 20:11:00 CST 2017, time=2017-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085739, encodeId=fa832085e39eb, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Feb 10 05:11:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718230, encodeId=25c61e1823048, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Thu Mar 30 14:11:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607222, encodeId=c0d7160e22263, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 18 11:11:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163549, encodeId=ead316354917, content=研究很不错,以前没太关注对认知的影响,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:37:41 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163502, encodeId=fc3c163502f9, content=有意义的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62d381629, createdName=yafeiliutjh, createdTime=Sat Dec 17 11:48:23 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163473, encodeId=3d201634e36d, content=β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161128/IMG583C2801690655672.jpg, createdBy=8d5d1986050, createdName=为了宝宝, createdTime=Sat Dec 17 10:35:03 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2016-12-17 为了宝宝

    β-阻断剂的使用在所有组中都产生了相当大的死亡率改善作用

    0

相关资讯

JACC:AMI女性患者更应该加强对心脏疾病风险的认知

在年轻急性心肌梗死(AMI)患者中,关于心脏危险因素,心脏风险感知的性别差异,以及有关的卫生保健提供者讨论的看法没有得到很好的研究。这项研究的目的是比较在住院治疗急性心肌梗死的男性和女性患者中,关于心脏危险因素普遍存在性,风险认知,卫生保健提供者的心脏疾病和风险修正的反馈意见的差异。研究人员共纳入了3,501例年龄18〜55岁的AMI患者于VIRGO研究中(在恢复中的变化:性别对年轻的AMI患者的

JAMA:呼吸机相关肺炎趋势研究

2006年到2012年,呼吸机相关肺炎(VAP)的发病率呈下降趋势;在医院和外科ICU里,2006年VAP从3.1/1000(呼吸机使用天数)下降到0.9/1000(下降71%);2012年则从5.2/1000下降到2.03.1/1000(下降62%)。自2005年以来,医保患者安全监测系统(MPSMS)独立测量VAP发生率。 本研究目的是,分析2005年到2013年MPSMS VAP发生率

JACC:AMI心源性休克后幸存,则出院早期死亡或再入院风险**

许多急性心肌梗死(AMI)和心源性休克患者住院后得以幸存;他们随后的预后是鲜为人知的。本研究旨在评估那些住院幸存者的心源性休克和出院后的死亡率以及全因住院之间的关联。该研究的参与者包括ACTION Registry–GWTG试验的≥65岁的急性心肌梗死患者,这些患者为住院幸存下来的患者,并且研究人员链接到这些患者的医疗保险索赔数据。研究人员使用比例风险模型来检测心源性休克和结果之间的关联,调整了患

JCO:老年AMI男性的维持治疗中添加雄激素,可显著改善生存

急性髓系白血病(AML)老年患者的预后不好,创新的维持治疗可以改善他们的预后。已有研究报告称,使用雄激素治疗再生障碍性贫血时,可以阻止AML细胞的增殖和启动。我们报告了一项多中心、III期、随机、开放标签试验结果,关于维持治疗中添加雄激素,对≥60岁患者的益处。 研究共纳入了330例AML患者,首次或第二次化疗或放疗治疗。诱导治疗包括去甲氧基柔红霉素 8 mg/m2 第1到5天,阿糖孢苷 1

AMI后心脏损伤全新分级标准意味着什么?

近日,上海交通大学医学院附属仁济医院心内科何奔教授团队,原创性地提出急性心肌梗死(AMI)后心脏损伤的全新分级标准,受到国内外学界的广泛关注。相关成果已在线发表在PLoS ONE杂志(PLoS One. 2015 Jun 19;10(6):e0130158.)。 美国斯坦福医院的David Hsi教授评价:“何奔教授与其团队以心肌梗死(MI)后心脏重构的病理生理机制为向导,利用心脏磁共振(M

Circulation:年轻AMI患者在出院30天内再入院概率和时间的性别差异

背景:年轻的女性(<65岁)急性心肌梗死后比年轻男性(AMI)要有2-3倍更大的死亡风险。如果这会因年龄而异,尚不清楚他们30天内再入院的风险是否会更高。研究人员考察了这种概率,时间和30天再入院主要诊断的性别差异,包括调整混杂因素的独立性的影响。    方法和结果:该研究包括年龄18-64岁的主要诊断为急性心肌梗死患者。数据是从加利福尼亚的医疗保健费用和项目国家住院